vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $124.5M, roughly 1.1× PagerDuty, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs 35.5%, a 94.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 4.7%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $24.1M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 5.9%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
ADMA vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $124.5M |
| Net Profit | $49.4M | $161.6M |
| Gross Margin | 63.8% | 85.3% |
| Operating Margin | 45.1% | 6.5% |
| Net Margin | 35.5% | 129.7% |
| Revenue YoY | 18.4% | 4.7% |
| Net Profit YoY | -55.9% | 2827.7% |
| EPS (diluted) | $0.20 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $124.5M | ||
| Q3 25 | $134.2M | $123.4M | ||
| Q2 25 | $122.0M | $119.8M | ||
| Q1 25 | $114.8M | $121.4M | ||
| Q4 24 | $117.5M | $118.9M | ||
| Q3 24 | $119.8M | $115.9M | ||
| Q2 24 | $107.2M | $111.2M | ||
| Q1 24 | $81.9M | $111.1M |
| Q4 25 | $49.4M | $161.6M | ||
| Q3 25 | $36.4M | $9.6M | ||
| Q2 25 | $34.2M | $-7.2M | ||
| Q1 25 | $26.9M | $-8.8M | ||
| Q4 24 | $111.9M | $-5.9M | ||
| Q3 24 | $35.9M | $-10.9M | ||
| Q2 24 | $32.1M | $-17.1M | ||
| Q1 24 | $17.8M | $-28.2M |
| Q4 25 | 63.8% | 85.3% | ||
| Q3 25 | 56.3% | 84.6% | ||
| Q2 25 | 55.1% | 84.0% | ||
| Q1 25 | 53.2% | 83.6% | ||
| Q4 24 | 53.9% | 83.0% | ||
| Q3 24 | 49.8% | 82.7% | ||
| Q2 24 | 53.6% | 82.6% | ||
| Q1 24 | 47.8% | 81.7% |
| Q4 25 | 45.1% | 6.5% | ||
| Q3 25 | 38.0% | 2.9% | ||
| Q2 25 | 35.1% | -8.6% | ||
| Q1 25 | 30.4% | -9.6% | ||
| Q4 24 | 32.6% | -8.7% | ||
| Q3 24 | 33.1% | -13.8% | ||
| Q2 24 | 36.6% | -19.5% | ||
| Q1 24 | 26.7% | -30.1% |
| Q4 25 | 35.5% | 129.7% | ||
| Q3 25 | 27.1% | 7.8% | ||
| Q2 25 | 28.1% | -6.0% | ||
| Q1 25 | 23.4% | -7.2% | ||
| Q4 24 | 95.2% | -5.0% | ||
| Q3 24 | 30.0% | -9.4% | ||
| Q2 24 | 29.9% | -15.4% | ||
| Q1 24 | 21.7% | -25.3% |
| Q4 25 | $0.20 | $1.69 | ||
| Q3 25 | $0.15 | $0.10 | ||
| Q2 25 | $0.14 | $-0.07 | ||
| Q1 25 | $0.11 | $-0.12 | ||
| Q4 24 | $0.45 | $-0.07 | ||
| Q3 24 | $0.15 | $-0.14 | ||
| Q2 24 | $0.13 | $-0.26 | ||
| Q1 24 | $0.08 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $547.8M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $320.5M |
| Total Assets | $624.2M | $1.0B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $547.8M | ||
| Q3 25 | $61.4M | $567.9M | ||
| Q2 25 | $90.3M | $597.1M | ||
| Q1 25 | $71.6M | $570.8M | ||
| Q4 24 | $103.1M | $542.2M | ||
| Q3 24 | $86.7M | $599.3M | ||
| Q2 24 | $88.2M | $592.8M | ||
| Q1 24 | $45.3M | $571.2M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | $477.3M | $320.5M | ||
| Q3 25 | $431.2M | $180.7M | ||
| Q2 25 | $398.3M | $145.7M | ||
| Q1 25 | $373.4M | $129.8M | ||
| Q4 24 | $349.0M | $111.6M | ||
| Q3 24 | $231.9M | $164.7M | ||
| Q2 24 | $188.3M | $174.0M | ||
| Q1 24 | $153.7M | $171.6M |
| Q4 25 | $624.2M | $1.0B | ||
| Q3 25 | $568.7M | $891.5M | ||
| Q2 25 | $558.4M | $926.8M | ||
| Q1 25 | $510.6M | $927.3M | ||
| Q4 24 | $488.7M | $866.8M | ||
| Q3 24 | $390.6M | $916.0M | ||
| Q2 24 | $376.4M | $924.0M | ||
| Q1 24 | $350.9M | $925.3M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $24.8M |
| Free Cash FlowOCF − Capex | $34.6M | $24.1M |
| FCF MarginFCF / Revenue | 24.8% | 19.3% |
| Capex IntensityCapex / Revenue | 0.8% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.72× | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $24.8M | ||
| Q3 25 | $13.3M | $34.0M | ||
| Q2 25 | $21.1M | $30.7M | ||
| Q1 25 | $-19.7M | $31.4M | ||
| Q4 24 | $50.2M | $22.1M | ||
| Q3 24 | $25.0M | $35.8M | ||
| Q2 24 | $45.6M | $28.6M | ||
| Q1 24 | $-2.2M | $22.2M |
| Q4 25 | $34.6M | $24.1M | ||
| Q3 25 | $-1.1M | $33.1M | ||
| Q2 25 | $18.7M | $30.2M | ||
| Q1 25 | $-24.4M | $30.3M | ||
| Q4 24 | $47.5M | $21.5M | ||
| Q3 24 | $24.0M | $35.1M | ||
| Q2 24 | $43.6M | $28.2M | ||
| Q1 24 | $-4.6M | $21.2M |
| Q4 25 | 24.8% | 19.3% | ||
| Q3 25 | -0.8% | 26.8% | ||
| Q2 25 | 15.3% | 25.2% | ||
| Q1 25 | -21.2% | 24.9% | ||
| Q4 24 | 40.4% | 18.1% | ||
| Q3 24 | 20.0% | 30.3% | ||
| Q2 24 | 40.7% | 25.4% | ||
| Q1 24 | -5.6% | 19.1% |
| Q4 25 | 0.8% | 0.6% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 0.4% | ||
| Q1 25 | 4.1% | 0.9% | ||
| Q4 24 | 2.3% | 0.5% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 0.4% | ||
| Q1 24 | 2.9% | 0.9% |
| Q4 25 | 0.72× | 0.15× | ||
| Q3 25 | 0.36× | 3.55× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
